2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2707

Scleroderma Renal Crisis: The Association of High-Dose Steroids and Poor Outcome
Abstract Number: 1225

Screening for Acquired Latent Tuberculosis in Patients with Rheumatoid Arthritis(RA) on Anti-Tnfα Therapy (TNF-I) in Southern California
Abstract Number: 1252

Screening for Tuberculosis before Initiating TNF Inhibitors: How Well Do We Do? a Nationwide Experience
Abstract Number: 2790

Screening of Patients with Adult-Onset Idiopathic Polyarteritis Nodosa for Deficiency of Adenosine Deaminase 2
Abstract Number: 1847

Screening Youth with Lupus for Depression and Anxiety in Pediatric Rheumatology Clinics
Abstract Number: 465

Seasonal Variation in Cutaneous Flares for Pediatric Lupus
Abstract Number: 2766

Seasonal Variation in Incidence of Giant Cell Arteritis: A Population-Based Cohort Study
Abstract Number: 2168

Seasonal Variation in Incidence of Polymyalgia Rheumatica: A Population-Based
Abstract Number: 2556

Secukinumab 150mg Provides Sustained Improvements in the Signs and Symptoms of Active Ankylosing Spondylitis with Consistent Safety Profile and High Retention Rate: 4-Year Results from a Phase III Trial
Abstract Number: 2564

Secukinumab Efficacy in Psoriatic Arthritis: Individual Patient Meta-Analysis of Four Phase 3 Trials in 2049 Patients
Abstract Number: 2585

Secukinumab Immunogenicity in Patients with Psoriatic Arthritis and Ankylosing Spondylitis during a 52-Week Treatment Period
Abstract Number: 2562

Secukinumab Improves Grappa-Omeract Core Domains of Psoriatic Arthritis
Abstract Number: 2386

Secukinumab Is a Promising Treatment for Patients with Juvenile Enthesitis Related Arthritis Nonresponsive to Anti-TNF Treatment
Abstract Number: 2583

Secukinumab Provides Early and Sustained Improvements in Health-Related Quality of Life in Patients with Ankylosing Spondylitis: A Pooled Analysis from the Secukinumab Phase 3 Trial Program
Abstract Number: 2553

Secukinumab Provides Early and Sustained Improvements in Health-Related Quality of Life in Patients with Psoriatic Arthritis: Pooled Results from the Secukinumab Phase 3 Trial Program

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].